STAT News

STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

بقلم STAT News

1 دقيقة قراءة
مشاركة
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

هل لديك أخبار لمشاركتها مع صناعة الفعاليات؟

أرسل بياناً صحفياً أو تلميحاً بقصة وتواصل مع آلاف المهنيين في مجال الفعاليات.

تواصل معنا→

المزيد في Health Tech

رؤى ذات صلة